Alaunos Therapeutics, Inc. · NASDAQ:TCRT
Alaunos Therapeutics — Technical Presentation (May 2026)
23 slides from Alaunos Therapeutics's technical presentation, May 26, 2026
Slide 1: Obesity and Metabolic Disorders Program
ALAUNSS’ THERAPEUTICS Obesity and Metabolic Disorders Program ] Results of Studies of ALN1003 in Diet-Induced Obese Mouse Model, May 2026
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements that are based on current expectations and assumptions that are subject to risks and uncertainties, which could cause actual results to differ materially. Important factors that could cause actual results to differ mate
Slide 3: Looking Beyond Weight Loss in Metabolic Dysfunction
Looking Beyond Weight Loss in Metabolic Dysfunction Oral, Non-incretin Approach to treat Opportunity Across Near Term Path Metabolic Diseases 3 Large Markets to IND Enabling Studies * ALN1003 is a preclinical, non- * Obesity: Validated by GLP-1/GIP * Preclinical and CMC activities to incretin, oral
Slide 4: ALN1003 Shows Preclinical Metabolic Improvement across Multiple Axes in DIO Mouse Model
ALN1003 Shows Preclinical Metabolic Improvement across Multiple Axes in Diet-Induced Obese (DIO) Mouse Model Non-hormonal Approach to Two non-GLP DIO studies Next Steps: Path to IND treat Metabolic Diseases demonstrate activity Enabling Studies * ALN1003 is a preclinical, oral, * Weight/Body composi
Slide 5: Two DIO Mouse Studies Show ALN1003 Activity Across Weight, Metabolic, and MASH-Relevant Liver Measures
Two DIO Mouse Studies Show ALN1003 Activity Across Weight, Metabolic, and MASH-Relevant Liver Measures Two non-GLP studies completed in DIO mice: * DIO Study 1: ALN1003 administered PO, BID at Low dose for 48 days : red study 2: ALN1003 administered via drinking water (DW) at Low, Mid and High doses
Slide 6: DIO Study 1: ALN1003 Produced a 10.3 Percentage-Point Lower Body-Weight Change vs Control at Day 48
; DIO Study 1: ALN1003 Produced a 10.3 Percentage-Point Lower Body-Weight Change vs Control at Day 48 Mean % Change in Body Weight cord Percentage-Point Change in Mean Body Weight of N So ~ a an “© WAI, PO, BID, 6hrs ALN1003 Group vs Control (WF) ALN1003 Low Dose, ® PO, BID, Ghrs 0. sesennnnntnnnnns
Slide 7: Significant reduction in Food Intake versus Control
Significant reduction in Food Intake versus Control Non-significant reduction in Water Intake versus Control Food Intake by Week Water Intake by Week “© WEI, PO, BID, 6hrs 100 ‘ALN1003 Low Dose, * 0, B10, 6hes 80 : 8 70) i => = = =: 60 1 7 1 2 3 4 5 6 7 50 Weeks on Treatment [--) i=} -® WI, PO, BID,
Slide 8: ALN1003 was associated with significantly lower liver weight
ALN1003 was associated with significantly lower liver weight, supporting further evaluation of hepatic effect Liver Weight w grams (SD) Nn 0. 12 0.08: @ WIPO, BID, 6 hes ‘A, ALN1008 Low Dose, PO, BID, éhrs 0.97: Ratio of Liver Weight : Body Weight (SD) ~ 8 é 2 0.00: Liver Wt as % of Body Weight 0.04
Slide 9: ALN1003 Improved Liver Injury / Cholestatic Markers
ALN1003 Improved Liver Injury / Cholestatic Markers Alkaline phosphatase 100: “ S74 ALP © WF, PO, 81D, ets 80,810, chs Alanine aminotransferase 400 eee © WEI, PO, BID, 6hrs_ INOS tow Ove © 0, Bib, 6hrs sa 300° g 2 3 200: oo) |. | a . 0 ALT Two-way factorial ANOVA, ** p<.01, **** p<0.0001, ns - not s
Slide 10: Histology; Blinded Pilot
Histology; Blinded Pilot Pathology Readout * H&E stains of liver tissue from DIO1/DIO2 were evaluated for NAS components and Masson’s trichrome for fibrosis. Three (3) control and 3 treatment samples per study, quantitatively selected. * Controls were reported at NAS 5, while ALN1003 samples average
Slide 11: DIO 1: Representative Images of Liver Histology
DIO 1: Representative Images of Liver Histology Representative image from HistoWiz pathology report, selected control sample _ Representative image from HistoWiz pathology report, selected ALN1003 low 2507101-08EL, with pathologist-reported NAS score 5/ steatotic liver disease- dose-treated sample 2
Slide 12: DIO 1: Representative Images of Liver Histology - Fibrosis
DIO 1: Representative Images of Liver Histology - Fibrosis Control (WFI) (sample 2507101-06EL) Masson’s Fibrosis grade 2, 40x magnification, 50um NON-CONFIDENTIAL Representative pathologist selected samples; these images are hypothesis generating only and not evidence of fibrosis reversal. Pilot pat
Slide 13: ALN1003 was associated with lower HOMA-IR after adjustment for percent body fat
ALN1003 was associated with lower HOMA-IR after adjustment for percents body fat, suggesting effects on insulin-resistance-related ully explained by adiposity alone biology not WHY IT MATTERS DIO Study 1: Fat % vs HOMA-IR * HOMA-IR is a calculated fasting glucose/insulin index commonly 607 @ Eg. use
Slide 14: ALN1003 showed significantly higher adiponectin-to-leptin ratio
ALN1003 showed significantly higher adiponectin-to- leptin ratio, suggesting improved metabolic profile + Adiponectin and leptin are adipose-derived endocrine markers associated with metabolic health and adipose tissue biology. In DIO Study 1, ALN1003 was associated with numerically lower leptin, si
Slide 15: DIO Study Conclusions
DIO Study 1 Conclusions * ALN1003 was tolerated throughout the study period, although mild, transient, reversible hypolocomotion was observed after dosing in approximately one-half of dose administrations. There were no similar observations in DIO control animals. * ALN1003 resulted in significant l
Slide 16: ALN1003 administered via drinking water produced dose-dependent weight loss in DIO mice
ALN1003 administered via drinking water produced dose-dependent weight loss in DIO mice; interpretation should consider reduced water consumption in treatment groups Change in Body Weight (%) ALN1003 Doses Consumed vs ABW% 10 Treatment Period (14 Days) Treatment Period PK Period 104 r 1. : ~~ WFI (D
Slide 17: Dose-dependent reductions in water consumption indicate administration-related limitations
Dose-dependent reductions in water consumption indicate administration-related limitations that should be addressed through optimized formulation and PK studies gicage (2 mice/cage) (SD) NON-CONFIDENTIAL Day 14 Cumulative Food Intake by Cage 100; 50; @ wrIoW) I ALN1003 4omglkg (DW) ‘A. ALN1003 120 m
Slide 18: Significant Improvement in Body Composition
Significant Improvement in Body Composition * After 17 days of ALN1003, changes in Body Composition using Bruker LF90OII: * Dose-dependent decrease in Fat% * Dose-dependent increase in Lean% * Dose-dependent decline in Fluid% * While lean percentage increased as a proportion of body weight, absolute
Slide 19: ALN1003 Treatment Reduced Weight of Liver in Dose-Dependent Manner
ALN1003 Treatment Reduced Weight of Liver in Dose- Dependent Manner, significantly at High Dose Representative images selected for illustration; not a blinded quantitative image analysis WFI/Control: Mouse 4 | | ALN1003 High Dose: Mouse 21 Liver weight in grams (SD) © wri fe N08 Low Dose ow ‘ALN1003
Slide 20: DIO 2: Masson's Trichrome Stain
DIO 2: Masson’s Trichrome Stain 2510082-0964 2510042-048, Control WF) CControt WF} 2810082-0564 CControt WF) 25100¢2-2061 ‘ALN1003 High Dose OW. 2510082-24. ign Dose OW -2510082-1961 ‘ALN1003 High Dose OW NON-CONFIDENTIAL Pilot pathology findings require confirmation in a powered MASH study. ALAUNOS
Slide 21: High-dose ALN1003 was associated with lower glucose, total cholesterol and HDL-C in DIO Study 2
High-dose ALN1003 was associated with lower glucose, total cholesterol and HDL-C in DIO Study 2 High-dose ALN1003 was associated with lower glucose, lower total cholesterol, and changes in HDL-C, the dominant lipoprotein in DIO mice Glucose Total Cholesterol High Density Lipoprotein Cholesterol 400-
Slide 22: DIO Study Conclusions
DIO Study 2 Conclusions * ALN1003 dosed via drinking water was feasible and well tolerated during the treatment period; although interpretation is limited by reduced water consumption and apparent dose aversion. Slight dehydration observed starting on Day 2 of PK period (D16) in 2 animals. * No hypo
Slide 23: ALN1003 Shows Preclinical Metabolic Improvement across Multiple Axes in DIO Mouse Model
ALN1003 Shows Preclinical Metabolic Improvement across Multiple Axes in Diet-Induced Obese (DIO) Mouse Model Non-hormonal ep enee treat Metabolic Path to IND Enabling Studies * ALN1003 is a preclinical, oral, non-hormonal * Additional preclinical development metabolic therapeutic candidate * CMC sca
Alaunos Therapeutics — Technical Presentation (May 2026) on 6ix